Results 211 to 220 of about 27,075 (224)

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of Oncology, 2019
Elżbieta Senkus-Konefka, Mark Robson, Pierfranco Conte   +2 more
exaly  

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

Annals of Oncology, 2014
Judith Balmaña, S J Isakoff, E Winer
exaly  

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Annals of Oncology, 2015
Eileen M. O'Reilly, Ian Chau, M R Middleton   +2 more
exaly  

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

Investigational New Drugs, 2016
Lesley Seymour, Lillian Siu, Eric Chen
exaly  

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

European Journal of Clinical Pharmacology, 2020
Maaike Bruin, Alwin D R Huitema, H Rosing   +2 more
exaly  

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Annals of Oncology, 2017
Gordon B. Mills, David B Solit, Carol Aghajanian   +2 more
exaly  

In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib

Xenobiotica, 2017
Helen Swaisland
exaly  

Olaparib

Reactions Weekly, 2016
openaire   +1 more source

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring or Versus Mutations

European Urology, 2019
Alan H. Bryce, Heather H Cheng, Catherine Handy Marshall   +2 more
exaly  

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

Radiotherapy and Oncology, 2015
Marcel Verheij, Conchita Vens
exaly